Eighty percent of all vaccines being administered across the country
Em um momento em que a vacinação em massa se tornou a linha de frente da sobrevivência coletiva, o Instituto Butantan — responsável por 80% das doses aplicadas no Brasil — interrompeu brevemente a produção da Coronavac por falta de insumos, revelando a fragilidade de uma cadeia de abastecimento que atravessa oceanos e burocrcias. A chegada prevista do ingrediente farmacêutico ativo até 20 de abril promete restaurar o ritmo e garantir a entrega de 46 milhões de doses ao programa nacional de imunização, mas o episódio deixa no ar uma pergunta mais profunda: até quando uma nação pode sustentar sua esperança de saúde pública dependendo do fluxo incerto de insumos vindos de outro continente?
- Em 7 de abril, as linhas de produção do Butantan pararam completamente — os estoques de matéria-prima se esgotaram e a fábrica mais vital do país ficou em silêncio.
- A interrupção ecoou por todo o programa nacional de vacinação, já que o instituto respondia por 80% das doses administradas no Brasil desde janeiro.
- O governador João Doria anunciou que um embaraço burocrático do lado chinês havia atrasado a entrega, mas que o ingrediente ativo chegaria até 20 de abril.
- Com o primeiro carregamento, Butantan poderá produzir 5 milhões de doses; um segundo lote, previsto para o fim do mês, viabilizará mais 10 milhões.
- A meta de 46 milhões de doses em abril permanece no horizonte — alcançável, mas suspensa sobre uma cadeia logística que já mostrou sua vulnerabilidade.
No dia 7 de abril, o Instituto Butantan ficou sem o ingrediente farmacêutico ativo necessário para continuar produzindo a Coronavac. A parada foi imediata. Para um estado que havia se tornado o principal fornecedor de vacinas do Brasil — responsável por 38,2 milhões de doses desde janeiro, ou 80% de tudo que foi aplicado no país —, o silêncio das máquinas tinha peso nacional.
No dia seguinte, o governo de São Paulo trouxe uma resposta. O insumo chegaria até 20 de abril, após um atraso causado por entraves burocráticos na documentação do lado chinês. Com esse carregamento, o Butantan poderia fabricar mais 5 milhões de doses e ainda cumprir o compromisso de entregar 46 milhões de doses ao programa nacional de imunização em abril.
A vulnerabilidade, porém, não era nova. A Coronavac é desenvolvida pela Sinovac, e o Brasil depende de remessas do ingrediente ativo vindas da China. Cada atraso alfandegário, cada problema de documentação, cada perturbação logística tem o poder de paralisar a produção. O episódio de abril foi um lembrete vivo dessa dependência.
O alívio veio em duas partes: além do carregamento de 20 de abril, um segundo lote — com três mil litros do ingrediente ativo, suficientes para mais 10 milhões de doses — estava programado para chegar ainda no mesmo mês. A meta de abril parecia segura. Mas a pergunta que persistia era mais ampla: conseguiria o Brasil manter esse ritmo de vacinação sem ser constantemente refém das incertezas de uma cadeia de suprimentos que começa do outro lado do Pacífico?
São Paulo's vaccine production engine hit a wall on April 7th when the Butantan Institute ran out of the raw material needed to keep making Coronavac doses. The stoppage was brief but urgent: the state's most critical supplier of coronavirus vaccines had nothing left to work with.
By the next morning, the São Paulo government had news. The active pharmaceutical ingredient—the chemical foundation of every Coronavac shot—would arrive by April 20th. Governor João Doria explained the delay had been bureaucratic, a documentation tangle on the Chinese end. Once that shipment landed, Butantan could manufacture five million more doses, which meant the state could still meet its April target: delivering 46 million doses to Brazil's national immunization program.
The timing mattered because Butantan had become the backbone of Brazil's vaccination effort. Since January, the institute had already shipped out 38.2 million doses. That represented 80 percent of all the vaccine doses being administered across the entire country. No other producer came close. When Butantan stopped, the nation's vaccination campaign felt the tremor.
The supply chain had been fragile from the start. Coronavac is a Chinese vaccine, developed by Sinovac, and Brazil depended on shipments of the active ingredient from across the Pacific. Every delay in documentation, every customs hold, every shipping disruption threatened to halt production. The April 7th stoppage was a reminder of that vulnerability—a moment when the institute's warehouses simply emptied out and the machines went quiet.
But the relief came quickly. Not only would the April 20th shipment restore production capacity for five million doses, but a second delivery was already scheduled for later in the month. That second batch would contain three thousand liters of the active ingredient, enough to manufacture another ten million doses. By the end of April, Butantan would have the raw materials to push production well beyond the 46-million-dose commitment.
What remained to be seen was whether the supply chain would hold. The institute had proven it could manufacture at scale and distribute across the country. What it could not control was the flow of ingredients from overseas. Every shipment was a negotiation with distance, bureaucracy, and the priorities of another nation's government. For now, the April deadline looked secure. But the deeper question—whether Brazil could sustain this pace of vaccination without constant interruptions—remained open.
Notable Quotes
Governor João Doria attributed the delay to bureaucratic documentation issues in China— São Paulo government statement
The Hearth Conversation Another angle on the story
Why did production stop so suddenly if this was such a critical operation?
Because the raw material came from China, and there was no buffer. Once the active ingredient ran out, there was nothing to process. It wasn't a manufacturing failure—it was a supply chain failure.
And Doria blamed documentation delays in China?
Yes. He said it was bureaucratic, a week's worth of paperwork problems. That's the kind of thing that sounds minor until your entire vaccine operation grinds to a halt.
Eighty percent of the country's vaccines came from Butantan. That's enormous pressure.
Enormous. And it meant that when Butantan stopped, the whole national campaign felt it. No other institute was producing at that scale.
So the April 20th deadline—was that firm?
The government said it was. But you can hear the contingency in the language. They were promising delivery by a certain date, but they were also announcing a second shipment coming later in the month. It felt like they were hedging.
What happens if that second shipment is also delayed?
Then you're back to the same problem. Ten million fewer doses in April. And the vaccination campaign slows down again.